Josh Bloom

Filter By:

Topic

Recent Commentary

Analysis and Commentary

Feds Battle Opioid Abuse With A Circular Firing Squad

by Henry I. Miller, Josh Bloomvia Daily Caller
Wednesday, August 29, 2018

In her classic treatise on blunders in public policy, Barbara Tuchman famously wrote: Mankind, it seems, makes a poorer performance of government than of almost any other human activity. In this sphere, wisdom, which may be defined as the exercise of judgment acting on experience, common sense and available information, is less operative and more frustrated than it should be.

Analysis and Commentary

Dianne Feinstein's Unscientific Chemical Scare Bill

by Henry I. Miller, Josh Bloomvia Washington Examiner
Friday, June 15, 2018

Chemicals surround us and make up everything in nature — everything we use, eat, and breathe. Yet the mere mention of the presence of chemicals is enough to scare some people.

Analysis and Commentary

Trump’s False War On Opioids Will Only Punish Patients In Pain

by Henry I. Miller, Josh Bloomvia Newsweek
Friday, April 6, 2018
The ongoing battle to control opioid addiction has not gone well, to say the least. Many of the government’s efforts, mostly from the Centers for Disease Control and Prevention (CDC), have been unproductive. Some have been counterproductive, medically and scientifically flawed, punitive, and perhaps most frightening, have usurped control of patient care from physicians.
Analysis and Commentary

Poorly Regulated 'Herbal Supplements' Could Be Your Worst Nightmare

by Henry I. Miller, Josh Bloomvia Forbes
Wednesday, February 24, 2016

The “dietary supplement” industry manufactures and sells more than vitamins, fish oil, and Echinacea. Way more. And some of its products could literally be your worst nightmare.

Pills
Analysis and Commentary

New Drugs For Hepatitis C Show Value Of Choices For Treatment

by Josh Bloom, Henry I. Millervia Forbes
Wednesday, January 14, 2015

The development of pharmaceuticals is among the riskiest of businesses. It now takes 10-15 years for a pharmaceutical company to get a new drug approved, and on average the cost exceeds $2.5 billion.